Zacks Investment Research on MSN
Why is CRISPR Therapeutics (CRSP) up 3.3% since last earnings report?
It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 3.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...
Investor's Business Daily on MSN
Stocks to watch: CRISPR Therapeutics sees relative strength rating rise to 82
CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.
Ark sold shares of Iridium Communications ( IRDM) worth over $14 million with transactions across ARKK, ARKQ and ARKX, ...
FNDA offers diversified small-cap exposure, attractive valuation versus indices, and lags VUG’s tech-heavy performance. Learn ...
Given these factors, my favorite index ETF to outperform in 2026 is the Vanguard Mega Cap Growth ETF as it's one of the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback